Caesars Sportsbook will launch its Caesars Racebook app this spring in partnership with NYRA Bets LLC, the New York Racing Association’s official online horse racing wagering platform.
Microsoft has never been shy about asking its customers for money — the $9.99 per month price for Microsoft 365 Family is proof of that. But you need to pay more, far more, than that to use Microsoft's new video editing app, Clipchamp, in the way you'd expect.
Clipchamp is being added to the stable of Windows apps as part of a new update this week. Though ostensibly for members of Microsoft's Windows Insider program, Clipchamp is an app that you can download from the Windows Store, and it seems reasonable that Microsoft will quietly foist Clipchamp onto new PCs, too.
The question is: Are you willing to pay for it?
Clipchamp is offered in a variety of pricing tiers, and, to be fair, there is a free version. Microsoft doesn't limit the number of video files that you can edit and export, nor does it limit the in-app features. All tiers of Clipchamp include a number of useful additions: a screen and camera recorder for meetings, synthesized text to speech, and access to stock footage, audio, and images. Microsoft also believes that a key selling feature of Clipchamp will be its professional-style timeline, allowing you to edit together video clips.
But Clipchamp clamps down hard once you want to export anything for uploading to a video service, sharing on social media, or submitting the finished video for a class assignment. The free tier is limited to a potato-like 480p video quality, and it's this video quality that Microsoft uses as the stick to force you to pay.
The next “Creator” tier, for example, limits output to 720p resolution, and charges you $9 per month for the privilege. Sure, there's unlimited cloud storage to go along with it, a precious resource that vanishes quickly when uploading video. Audio stock files, as well, are also unlimited.
However, it's only the Business tier, at $19/mo, where Clipchamp allows you to export video at 1080p resolution. For that, you get everything that the Creator tier offers, plus a “brand kit” where you can apply your own superimposed logos. The Business Platinum tier (at $39/mo, ouch!) is where you can unlock Clipchamp's full potential: unlimited cloud storage, audio, video, and image stock — but still, 1080p resolution.
Microsoft hasn't said whether it will adjust Clipchamp's pricing, offer discounts to those who already subscribe to other services like Microsoft 365, or otherwise ease the financial burden. (When PCWorld asked these questions of Microsoft, we were told via email: “Nothing to share at this time.”)
We can hope that Microsoft will: “Clipchamp is a natural fit to extend the cloud-powered productivity experiences in Microsoft 365 for individuals, families, schools, and businesses,” Chris Pratley, Microsoft's corporate vice president of the Office Media Group wrote in announcing the new acquisition.
It's easy to say that Clipchamp's pricing pales in comparison to Adobe: a subscription to Adobe Premiere Pro, for example, is $20.99 per month, while After Effects' motion graphics app is also $20.99/mo and access to Adobe's stock footage, Adobe Stock, is an extra $29.99/mo. But these are professional applications for professional budgets.
Still, there certainly has to be room for some adjustment. Sharing a 480p video is grounds for mockery on social media, rather than marveling at what the video actually shows. People won't be creating many homemade videos of a child's birthday party, graduations, and weddings at that bitrate. And there's something intrinsically unsettling about Microsoft adding what's essentially another upsell onto Windows PCs. We tolerate antimalware subscription promotions, trials of Hulu and Netflix, and cloud storage offerings like Dropbox, but a fundamentally basic app like video editing?
Yes, Microsoft still offers a free video editor in Windows (Video Editor), but now there's two? Ugh. Figure it out, Microsoft. Between Microsoft 365 and Adobe and cloud gaming and Netflix and the entirety of streaming services, another damn subscription se
ems entirely too much to bear.
Medical equipment and supplies from Canadian NGOs were successfully transferred to Ukraine conflict victims through Warsaw, Poland, on a special Air Canada Boeing 787-9 humanitarian cargo charter trip. Tons of much-needed equipment, such as medical beds, plastic mattresses, and other […]
TOKYO, Mar 11, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today the company will present research from its robust Alzheimer's disease (AD) pipeline, including the latest findings on lecanemab, Eisai's investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of early AD at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) from March 15-20 in Barcelona, Spain and virtually.
The lecanemab data and additional research findings from Eisai's clinical development programs will be featured in 13 presentations. Lecanemab was granted Breakthrough Therapy and Fast Track designations by the U.S. Food and Drug Administration (FDA) in June and December 2021, respectively. Eisai anticipates completing lecanemab's rolling submission of a Biologics License Application for the treatment of early AD to the FDA under the accelerated approval pathway in the first quarter of Eisai's fiscal year 2022, which begins April 1, 2022. Additionally, the readout of the Phase 3 confirmatory Clarity AD clinical trial will occur in the Fall of 2022. Eisai initiated a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) of application data of lecanemab under the prior assessment consultation system in Japan in March 2022.
"Four key presentations at AD/PD 2022 advance our understanding of the mechanism of action of Eisai's investigational anti- Abeta protofibril antibody lecanemab and the therapy's clinical and safety profile, including amyloid related imaging abnormalities, or ARIA, from the Phase 2b study and open-label extension, in the potential treatment of early Alzheimer's disease," said Michael Irizarry, M.D., Senior Vice President, Deputy Chief Clinical Officer, Neurology Business Group, Eisai Inc. "In addition to lecanemab, Eisai's robust pipeline includes compounds targeting the tau pathway, other pathways leading to neurodegeneration, and the testing of combination therapies that may be the optimal approach to treat or even prevent Alzheimer's disease."
The focus on AD has historically been on alleviating cognitive, functional, and behavioral symptoms, but there has been significant progress in understanding the biological mechanisms of the disease. Eisai's investigational pipeline aims to treat the range of underlying pathophysiology, including amyloid, tau and neurodegeneration.
"Because of the robust design of the lecanemab Phase 2b study, Eisai was able to design the Phase 3 confirmatory Clarity AD clinical trial to optimally verify lecanemab's clinical efficacy and safety in early Alzheimer's disease," said Ivan Cheung, Chairman, Eisai Inc., Senior Vice President, President Neurology Business Group and Global Alzheimer's Disease Officer, Eisai Co., Ltd. "Part of the recruitment strategy for the Clarity AD confirmatory trial was to ensure greater inclusion of ethnic and racial populations. While there is still important work to be done in ensuring minority populations' participation in clinical trials, Eisai is proud that approximately 25% of the total U.S. enrollment in Clarity AD consists of African American and Hispanic persons living with early Alzheimer's disease, which mirrors the U.S. Medicare population."
This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agent will successfully complete clinical development or gain health authority approval.
Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comEisai Co., Ltd. announced today the company will present research from its robust Alzheimer's disease (AD) pipeline, including the latest findings on lecanemab, Eisai's investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of early AD at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) from March 15-20 in Barcelona, Spain and virtually.
SÃO PAULO, Brazil, SAN JOSE, Calif., and TOKYO, Japan , Mar 11, 2022 - (JCN Newswire) - Cisco and NEC Corporation today announced that Telefonica Vivo is deploying a simplified and automated, 5G-ready IP network for its converged mobile and fixed networks as part of the Fusion Network Project in Brazil supported by industry-leading solutions from the vendors. Cisco and NEC have been closely collaborating in Brazil for over 10 years and now are a part of a Global System Integrator Agreement (GSIA) signed in 2020, enabling them to seamlessly deploy an automated transport 5G-ready network for Telefonica Vivo.
Telefonica designed the Fusion Network Project as a platform for incorporating services into a single network infrastructure, offering advanced communications services, and transforming the customer experience. Leveraging the power of automation, the project aims to offer a more agile, scalable, and flexible network with improved reliability for both residential users and enterprises in the 5G era.
As defined in the Fusion Network Project, Cisco and NEC will work together to optimize Telefonica Vivo's total cost of ownership (TCO) and increase business agility by simplifying its network architecture and operations, converging mobile and fixed networks, and automating multi-layer networks across packet, optical and microwave domains. In addition, Segment Routing IPv6 will be implemented to enable a unified architecture with network slicing capabilities.
The simplification and automation of a multi-domain, multi-layer converged network coupled with segment routing, will increase Telefonica Vivo's network scalability and flexibility as it prepares to launch 5G. The Fusion Network Architecture will provide the scalability and flexibility needed to design and deliver new services.
As part of the agreement, Cisco will provide industry-leading network equipment including ASR 9000 and NCS 540 series routers for IP transport, Cisco Crosswork Network Controller as the multi-vendor SDN solution, and Cisco Crosswork Hierarchical Controller to enable multi-vendor and multi-layer automation within the Fusion Network domain. Cisco will serve as the key networking advisor leveraging a long-standing relationship and in-depth understanding of Telefonica Vivo's network.
Also building on a strong relationship and knowledge of the Telefonica Vivo network, NEC will serve as the key network integrator and provide local engineering capabilities with 5G xHaul transformation services to deliver a scalable migration for thousands of nodes.
"Since the transport network will play a key role in supporting innovative customer experiences and new services built on 5G, we needed trusted partners with a solid track record and local delivery capabilities," said Elmo Matos, Planning Director, Telefonica Vivo.
"Building on our partnership with NEC, we are pleased to enable Telefonica Vivo in providing faster, more seamless connections through a more modern, simplified network," said Shaun McCarthy, Vice President of Worldwide Sales, Mass Infrastructure Group, Cisco. "It is a great honor for Cisco to help be the bridge that is bringing the Internet for the Future to Brazil."
"NEC is honored to be selected as key partner for the Fusion Network Project, which is foundational to blossoming digital experiences in 5G," said Mayuko Tatewaki, General Manager, Service Provider Solutions Division, NEC Corporation. "With Cisco's trusted solutions combined into NEC's 5G xHaul Automation Ecosystem and further extended by our network integration capabilities globally and regionally, we are confident the implementation of the next-gen network will help deploy immersive 5G services in Brazil."
About Telefonica
Telefonica is a leading telecommunications service provider globally. The company offers fixed and mobile connectivity, as well as a wide range of digital services for individual consumers and enterprises. Telefonica has 367 million clients spanning Europe and Latin America. Telefonica is a private company whose shares are listed as TEF on the Bolsa de Madrid, the New York Stock Exchange, and the Bolsa de Valores de Lima.
Cisco (NASDAQ: CSCO) is the worldwide leader in technology that powers the Internet. Cisco inspires new possibilities by reimagining your applications, securing your data, transforming your infrastructure, and empowering your teams for a global and inclusive future.
Cisco and the Cisco logo are trademarks or registered trademarks of Cisco and/or its affiliates in the U.S. and other countries. A listing of Cisco's trademarks can be found at new windowwww.cisco.com/go/trademarks. Third-party trademarks mentioned are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company.
About NEC Corporation
NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of "Orchestrating a brighter world." NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com.
Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comCisco and NEC Corporation today announced that Telefonica Vivo is deploying a simplified and automated, 5G-ready IP network for its converged mobile and fixed networks as part of the Fusion Network Project in Brazil supported by industry-leading solutions from the vendors.
Silicon Valley luminaries, led by Apple alumnus and NeXT Computer co-founder Rich Page, to support the company’s technology development, data and analytics, and consumer engagement strategy NEW YORK–(BUSINESS WIRE)–$PAVM #DigitalHealth—PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company today announced that its majority-owned digital health subsidiary Veris Health (“Veris”) has launched a […]